MarketMeter Market Insights: What IML's Whittaker, Paradice's Gagic & Blackwattle's Riordan are watching
MarketMeter Market Insights: What IML's Whittaker, Paradice's Gagic & Blackwattle's Riordan are watching
About this video
Key points
Investors prioritise alignment, accountability, conservatism and consistency in management behaviour
Persistent earnings misses, accounting “massaging” and governance breakdowns are major red flags
Healthcare leaders like (ASX:CSL), (ASX:COH) and (ASX:RHC) are, in Paradice's view, struggling to meet historic expectations
The latest MarketMeter Market Insights event focuses on how professional investors assess management quality, governance and execution risk across the Australian market.
Tim Riordan from Blackwattle, Jovana Gagic from Paradice Investment and Marc Whittaker from IML emphasise that alignment, accountability, conservatism and consistency are core frameworks the buy side applies when judging corporate performance. Repeated earnings misses, shifting KPI definitions and opaque adjustments are presented as key warning signs that can rapidly erode market confidence.
Whittaker highlights the appeal of “halo” style, predictable businesses such as Cleanaway (ASX:CWY), arguing that stable cash flows and an “AI‑proof” waste collection model look undervalued after cost‑driven share price weakness. He also points to takeover activity in names such as ClearView Wealth (ASX:CVW) and Steadfast Group (ASX:SDF) as, in his view, evidence that public markets can underprice long‑term value, drawing in corporate buyers.
Gajic cites healthcare as a sector where former market darlings CSL (ASX:CSL), Cochlear (ASX:COH) and Ramsay Health Care (ASX:RHC) repeatedly disappoint relative to legacy expectations. She prefers smaller healthcare names such as Sonic Clinical Labs’ peer Australian Clinical Labs (ASX:ACL) and Integral Diagnostics (ASX:IDX), suggesting that management change and clearer margin delivery targets can reset credibility.
Across sectors, all three investors stress that boards must genuinely challenge CEOs, ensure skin in the game and align incentives with long‑term shareholder outcomes.